1-5 of 5
Lena Kanter, MD, PhD
Close
Sort by
Journal Articles

Modulation of Leukotriene Signaling Affecting Cell Growth in Chronic Myeloid Leukemia: A Key Pathway to Cure?

Elham Yektaei, PhD, Anders Nilsson, PhD, Barbro Näsman-Glaser, MSc, Marja Ekblom, MD PhD, Hong Qian, PhD, Olof Rådmark, PhD, Ana Zovko, PhD, Lena Kanter, MD PhD, Jonas Wallvik, MD PhD, Leif Stenke, MD PhD
Journal: Blood
Blood (2015) 126 (23): 5137.
https://doi.org/10.1182/blood.V126.23.5137.5137
Published: 2015
Journal Articles

Gene Array Biomarkers in Acute Myeloid Leukemia to Predict Remission Duration.

Marita Lagergren Lindberg, MD, Petra Hååg, PhD, Ali Moshfegh, PhD, Lena Kanter, MD, PhD, Rolf Lewensohn, MD, PhD, Kristina Viktorsson, PhD, Leif Stenke, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 3466.
https://doi.org/10.1182/blood.V114.22.3466.3466
Published: 2009
Journal Articles

Analysis of γH2AX and NHEJ Signaling as Molecular Determinants for GOSensitivity in AML

Petra Hååg, PhD, Marita Lagergren Lindberg, MD, Lena Kanter, MD, PhD, Rolf Lewensohn, MD, PhD, Leif Stenke, MD, PhD, Kristina Viktorsson, PhD
Journal: Blood
Blood (2008) 112 (11): 4854.
https://doi.org/10.1182/blood.V112.11.4854.4854
Published: 2008
Journal Articles

The Importance of CD33 Expression and Pro-Apoptotic Signalling for Gemtuzumab Ozogamicin-Induced Cytotoxic Effects on AML Cells

Marita Lagergren Lindberg, MD, Petra Hååg, PhD, Kristina Viktorsson, PhD, Lena Kanter, MD, PhD, Rolf Lewensohn, MD, PhD, Leif Stenke, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 5041.
https://doi.org/10.1182/blood.V112.11.5041.5041
Published: 2008
Journal Articles

Global Proteomics in AML: Using SELDI-TOF MS on Diagnostic Samples To Identify Spectra and Protein Biomarkers Indicative of Prognosis.

Leif Stenke, MD, PhD, Maria Pernemalm, MSC, Jenny Forshed, PhD, Yodi Pawitan, PhD, Marita Lagergren-Lindberg, MD, Lena Kanter, MD, PhD, Janne Lehtiö, PhD
Journal: Blood
Blood (2006) 108 (11): 4436.
https://doi.org/10.1182/blood.V108.11.4436.4436
Published: 2006